Blood Test Checks Insulin-Making Cells in Children With Type 1 Diabetes
Tests a blood marker in children with type 1 diabetes and healthy children.
Plain-language title generated from the registry record
Registry title: Anhydroglucitol in Children With Type 1 Diabetes
Key facts
- Where
- Geneva, SwitzerlandSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 18 years old?
Source: NCT05594706, who can take part
Where in Switzerland
- University Hospital of GenevaGeneva, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Geneva
- Trial code
- NCT05594706
- Record updated
- 18 May 2026
- Original description
The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.Read full original descriptionShow less
Anhydroglucitol as a Measure of the Functional Beta-cell Mass in Children With Type 1 Diabetes - Pilot Study
The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.
Inclusion: Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8; Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID); Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM); Patient willing to keep the same type of CGMS or FGM during the year of observation; Ability to give informed consent as documented by signature.
Exclusion: Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM; Patients changing the type of CGMS during the course of the study.